United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

benecare medical -

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - lucentis is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to choroidal neovascularisation (cnv)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)

European Union - English - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv)

United States - English - NLM (National Library of Medicine)

bejing rimeng biological technology co ltd - salicylic acid  0.5% - salicylic acid    scalp protectant ■ shake well before use ■ apply to scalp twice a day ■ apply sufficient amount to intended area rash, irritation and/or abnormal reaction develop and last.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

benefoot uk ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

benefoot uk ltd -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

benefoot uk ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

rehacare pty ltd - 33056 - bandage, cast - polyester, fibreglass and plaster used to construct a stiff dressing (cast) in order to immobilize bone fractures, diseased joints, or painful sprains.